2019 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2019)

SOX, UFT/LV show similar DFS in high-risk stage III colon cancer

Elaine Soliven, 20190311000000

Adjuvant chemotherapy using S-1 plus oxaliplatin (SOX) or tegafur-uracil/leucovorin (UFT/LV) led to similar disease-free survival (DFS) rates in patients with high-risk stage III colon cancer, according to updated results of the ACTS-CC 02* presented at ASCO GI 2019.

Add-on neoadjuvant chemo to surgery ups survival in advanced pancreatic cancer

Elaine Soliven, 20190308092220

Neoadjuvant chemotherapy (NACT) followed by surgery was significantly associated with better disease-free survival (DFS) and overall survival (OS) in patients with LAPC* compared with upfront surgery, according to a study presented at the ASCO Gastrointestinal Cancers Symposium 2019 (ASCO GI 2019).

Adjuvant durvalumab prolongs RFS in oesophageal adenocarcinoma

Elaine Soliven, 20190306000000

Adjuvant treatment with durvalumab, a PD-L1 inhibitor, following trimodality therapy may improve relapse-free survival (RFS) in patients with locally advanced oesophageal adenocarcinoma (LA-EAC) or gastroesophageal junction (GEJ) adenocarcinoma who did not achieve pCR* after neoadjuvant chemoradiation, according to a small study presented at the ASCO Gastrointestinal Cancers Symposium 2019 (ASCO GI 2019).

Ramucirumab improves survival in patients with advanced HCC and elevated α-fetoprotein

Roshini Claire Anthony, 20190301140307

Patients with advanced hepatocellular carcinoma (HCC) and elevated α-fetoprotein concentration who were previously treated with sorafenib had improved overall survival (OS) and progression-free survival (PFS) following treatment with ramucirumab, according to results of the phase III REACH-2* trial.

REFLECT offers insights on OR as predictor of survival in HCC patients

Pearl Toh, 20190227190010

Responders showed better overall survival (OS) than nonresponders to treatment for hepatocellular carcinoma (HCC), according to an exploratory analysis of the REFLECT trial, suggesting that objective response (OR) is an independent predictor of OS in these patients.

Trifluridine/tipiracil: Benefits persist regardless of surgery for heavily pretreated gastric cancer

Pearl Toh, 20190225190010

Whether patients had prior gastrectomy did not attenuate the survival benefit conferred by oral trifluridine/tipiracil for those with heavily pretreated metastatic gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, according to new updates from the TAGS study presented at ASCO GI Cancers Symposium (GICS) 2019.

Andecaliximab disappoints in gastric cancer

Audrey Abella, 20190215100000

The addition of the monoclonal antibody andecaliximab to nivolumab or a chemotherapy regimen (modified FOLFOX6*) did not provide survival benefit in patients with pretreated metastatic or untreated HER2-negative gastric/gastroesophageal (G/GEJ) adenocarcinoma, according to data presented at ASCO GI 2019.

Tislelizumab + chemo exhibits favourable tolerability for gastric cancer, oesophageal SCC

Audrey Abella, 20190214020628

The addition of the investigational, humanized IgG4* monoclonal antibody tislelizumab to chemotherapy was generally well-tolerated and generated favourable antitumour activity in patients with advanced gastric/gastroesophageal (G/GEJ) cancer and oesophageal squamous cell carcinoma (SCC), according to data presented at ASCO GI 2019.

FOLFOX-paclitaxel combo shows potential for advanced gastric cancer in first-line setting

Roshini Claire Anthony, 20190212140306

The combination of paclitaxel and FOLFOX led to an improvement in progression-free survival (PFS) compared with FOLFOX alone among chemotherapy-naïve patients with advanced gastric cancer, according to results from the phase II FNF-004* trial presented at ASCO GI 2019.

Neoadjuvant gemcitabine plus S-1 improve OS in pancreatic cancer

Christina Lau, 20190201100923

Neoadjuvant chemotherapy with gemcitabine plus S-1 has been shown to improve overall survival (OS) in patients with resectable pancreatic ductal adenocarcinoma in a Japanese study.